KV-001
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Pre-clinicalActive
Key Facts
Indication
Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
Phase
Pre-clinical
Status
Active
Company
About Kinvard Bio
Kinvard Bio is a private, preclinical-stage biotech developing oxepanoprolinamide (OPP) antibiotics to combat the global antimicrobial resistance (AMR) crisis. Its proprietary platform designs molecules preorganized for optimal binding to the bacterial ribosome, aiming to bypass existing resistance mechanisms and treat a broad spectrum of Gram-positive, Gram-negative, and nontuberculous mycobacterial infections. The company's strategy focuses on high-unmet-need areas like hospital-acquired infections and chronic respiratory diseases, with a pipeline designed for both IV and oral delivery to enable flexible treatment regimens.
View full company profileTherapeutic Areas
Other Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Drugs
| Drug | Company | Phase |
|---|---|---|
| Acute Programme | Santero Therapeutics | Pre-clinical/Research |